TABLE 1.
Baseline characteristics, clinical presentation, and management of the 174 patients with confirmed SARS-CoV-2 infection
| Convalescent plasma(n = 58) | Matched control(n = 116) | P | |
|---|---|---|---|
| Baseline characteristics | |||
| Age, median (IQR) | 50 (40–58) | 50 (42–61) | 0.676 |
| Male gender, n (%) | 39 (67) | 78 (67) | >0.999 |
| BMI >30 kg/m2, n (%) | 18 (31) | 36 (31) | >0.999 |
| Deceased donor transplants, n (%) | 28 (51) | 56 (50) | 0.956 |
| Prior transplant, n (%) | 2 (3.6) | 6 (5.4) | >0.999 |
| Months after transplant, median (IQR) | 72 (29–139) | 73 (31–134) | 0.926 |
| Immunosuppression, n (%) | 0.838 | ||
| TAC-AZA | 18 (31) | 40 (35) | |
| TAC-MPA | 19 (33) | 38 (33) | |
| TAC-mTORi | 7(12) | 11 (9.6) | |
| Other | 14 (24) | 27 (22.5) | |
| Steroids use, n (%) | 55 (98) | 114 (98) | >0.999 |
| High steroid dose within the previous 3 mo, n (%) | 2 (3.9) | 1 (0.9) | 0.231 |
| Antithymocyte globulin within the previous 3 mo, n (%) | 2 (3.9) | 1 (0.9) | 0.231 |
| Use ACE or ARB, n (%) | 18 (33) | 43 (39) | 0.500 |
| Current of former smoker, n (%) | 9 (44) | 28 (30) | 0.265 |
| Hypertension, n (%) | 42 (72) | 91 (78) | 0.377 |
| Diabetes, n (%) | 21 (36) | 39 (34) | 0.735 |
| Heart disease, n (%) | 2 (3.4) | 0 (0) | 0.110 |
| CKD-EPI creatinine eGFR at baseline, median (IQR) | 52 (37–64) | 50 (34–62) | 0.725 |
| Days from symptoms onset to COVID-19 diagnosis, median (IQR) | 3 (2–4) | 3 (2–5) | 0.458 |
| COVID-19 WHO severity score at presentation, n (%) | 0.033 | ||
| 1—Ambulatory, asymptomatic; viral RNA detected | 0 | 1 (0.9) | |
| 2—Ambulatory, symptomatic; independent | 46 (79.3) | 62 (53.4) | |
| 3—Ambulatory, symptomatic; assistance needed | 11 (19) | 45 (38.8) | |
| 4—Hospitalized; no oxygen therapy | 1 (1.7) | 2 (1.7) | |
| 5—Hospitalized; oxygen by mask or nasal prongs | 0 | 4 (3.4) | |
| 6—Hospitalized; oxygen by NIV or high flow | 0 | 2 (1.7) | |
| Pharmacological treatment during COVID-19,a n (%) | |||
| High-dose steroids | 21 (37.5) | 48 (44.4) | 0.393 |
| Azithromycin | 5 (8.9) | 24 (22.2) | 0.034 |
| Other antibiotics | 20 (35.7) | 42 (38.2) | 0.756 |
| Hydroxychloroquine | 0 | 2 (1.7) | 0.301 |
| Ivermectin | 0 | 2 (1.7) | 0.301 |
| Monoclonal antibodies | 0 | 0 | – |
| Remdesivir | 0 | 0 | – |
| Immunosuppression during COVID-19, n (%) | |||
| No changes | 38 (65.5) | 67 (58) | 0.606 |
| Suspension of MPA/mTORi/AZA | 7(12) | 14(12) | |
| Suspension of all drugs except for steroids | 13 (22.5) | 28 (24) | |
| Missing information | 0 | 7 (6) | |
| Outcomes | |||
| Need for oxygen therapy | 72% | 68% | 0.684 |
| Mechanical ventilation | 28% | 32% | 0.684 |
| Death | 22% | 24% | 0.950 |
Bold types means P < 0.05. aOne patient might have used >1 pharmacological treatment during COVID-19.
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; AZA, azathioprine; BMI, body mass index; CKD-EPI, chronic kidney disease epidemiology collaboration; COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; IQR, inrequartile range; MPA, mycophenolic acid; mTORi, m-TOR inhibitors; NIV, non Invasive ventilation; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TAC, tacrolimus.